ClinicalTrials.Veeva

Menu

Posturography-Neuropathy (PONE)

U

University Hospital, Lille

Status

Enrolling

Conditions

Neuropathy Demyelinating

Treatments

Other: Motion analysis

Study type

Interventional

Funder types

Other

Identifiers

NCT04154540
2017_17
2017-A02861-52 (Other Identifier)

Details and patient eligibility

About

If the classification between hereditary and acquired neuropathy is often easy, there is no completely specific marker allowing the distinction between the two etiologies. Clinical experience suggests that hereditary neuropathies have less impact on balance and gait than the acquired neuropathies at equivalent level of impairment, but this has never been clearly demonstrated.

Enrollment

52 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • CMT1A for molecular-proven Group 1 (PMP22 duplication)
  • IPDC likely or defined for Group 2
  • Able to walk 10 m unassisted

Exclusion criteria

  • Neurological history other than neuropathy: epilepsy, stroke, dementia
  • Pregnant women
  • Person under guardianship or trusteeship
  • Musculoskeletal conditions other than neuropathy impairing walking abilities
  • Major comorbidity considered a contraindication by the investigator (cancer, unstable angor, etc.)

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

52 participants in 2 patient groups

demyelinating hereditary neuropathy
Experimental group
Description:
adult patients with demyelinating hereditary neuropathy type CMT 1A.
Treatment:
Other: Motion analysis
demyelinating inflammatory neuropathy
Experimental group
Description:
adult patients with acquired demyelinating inflammatory neuropathy.
Treatment:
Other: Motion analysis

Trial contacts and locations

1

Loading...

Central trial contact

Céline TARD, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems